Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.43 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.41 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.41 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.41 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.40 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544819 | 0.98 | AOC3 (0.56) | AOC3TSHRALDH1A1CA2CARM1 | |
| SCHEMBL27493772 | 0.89 | ALDH1A1 (0.50) | AOC3TSHRALDH1A1CA2CARM1 | |
| SCHEMBL7598746 | 0.86 | AOC3 (0.45) | AOC3TSHRALDH1A1CA2CARM1 | |
| Hydrochloric Acid SCHEMBL9518503 | 0.86 | SLC6A2 (0.46) | AOC3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9518675 | 0.86 | ESR1 (0.46) | AOC3TSHRALDH1A1CYP2C19ESR1 | |
| SCHEMBL28044331 | 0.85 | CYP19A1 (0.53) | AOC3ALDH1A1CA2CYP2C19GLA | |
| SCHEMBL12016039 | 0.83 | TP53 (0.50) | AOC3TSHRALDH1A1CARM1PRMT6 | |
| SCHEMBL28980138 | 0.83 | AOC3 (0.47) | AOC3TSHRALDH1A1CYP2C19GRIN2B | |
| SCHEMBL9879437 | 0.83 | SLC6A2 (0.47) | AOC3TSHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28901400 | 0.82 | CRHBP (0.58) | TSHRALDH1A1NPC1LOXL2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080071091-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | WYETH (US) | 2008-03-20 | — | — | US | claimed |
| US-7323483-B2 | Processes and compounds for the preparation of substituted naphthylindole derivatives | WYETH (US) | 2008-01-29 | — | — | US | claimed |
| CN-101111491-A | Process and compounds for the preparation of substituted naphthylindole derivatives | WYETH CORP (US) | 2008-01-23 | — | — | CN | claimed |
| EP-1856104-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | Wyeth a Corporation of the State of Delaware (US) | 2007-11-21 | — | — | EP | claimed |
| US-20060183917-A1 | Processes and compounds for the preparation of substituted naphthylindole derivatives | WYETH (US) | 2006-08-17 | — | — | US | claimed |
| WO-2006081455-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | WYETH (US) | 2006-08-03 | — | — | WO | claimed |
| US-20080071091-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | WYETH (US) | 2008-03-20 | — | — | US | disclosed |
| CN-101146770-A | 2-phenyl indoles as prostaglandin D2 receptor antagonists | AVENTIS PHARMA INC (US) | 2008-03-19 | — | — | CN | disclosed |
| US-7323483-B2 | Processes and compounds for the preparation of substituted naphthylindole derivatives | WYETH (US) | 2008-01-29 | — | — | US | disclosed |
| CN-101111491-A | Process and compounds for the preparation of substituted naphthylindole derivatives | WYETH CORP (US) | 2008-01-23 | — | — | CN | disclosed |
| EP-1856104-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | Wyeth a Corporation of the State of Delaware (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1844011-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060183917-A1 | Processes and compounds for the preparation of substituted naphthylindole derivatives | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
| WO-2006081343-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006081455-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | WYETH (US) | 2006-08-03 | — | — | WO | disclosed |
| US-4642280-A | PHTHALOCYANINES; SENSITIVE, STABLE, LOW RESIDUAL VOLTAGE | MINOLTA CAMERA KABUSHIKI KAISHA (JP) | 1987-02-10 | — | — | US | disclosed |
| US-4531963-A | Promoting germination of oil seeds | THE UPJOHN COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
| US-4252958-A | ACETONE COMPOUND, AMMONIA DONER, HYDRAZINE HYDROHALIDE CATALYST | ARGUS CHEMICAL CORPORATION (US) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, CYSLTR2 | CA2 1065/4885GLA 2210/4885GRIN2D 900/4885 |
| US-20080071091-A1 | PROCESSES AND COMPOUNDS FOR THE PREPARATION OF SUBSTITUTED NAPHTHYLINDOLE DERIVATIVES | SERPINE1, SERPINB1, TFPI | CA2 3846/4885GLA 979/4885GRIN2D 4722/4885 |
| US-20060183917-A1 | Processes and compounds for the preparation of substituted naphthylindole derivatives | SERPINE1, SERPINB1, TFPI | CA2 3846/4885GLA 979/4885GRIN2D 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.